logo

CAMP

CAMP4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.60 / 10
Netural

Fund flow evaluation is 7.35/10, classified as favorable, with Small-scale inflows showing a positive trend despite negative signals in larger blocks. Analyst coverage is limited to three institutions; two recent ratings are Buy (66.7%) and one is Neutral (33.3%), producing a weighted rating of 1.85 and a MarketComprehensiveAnalysis indicating mismatched expectations. The recent 8.6% drop from a $30 million share offering adds near-term pressure. Together, the strong fund flow and mixed analyst sentiment create a neutral-to-slightly-positive sentiment backdrop that partially offsets the weak fundamentals and technicals.

FundamentalSentiment(4.6)Technical
Fund Flow Rating
Analyst RatingBuy

Wall Street Opinions

Buy

Strong Buy

0%

Buy

67%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-09-16
InstitutionJP Morgan
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for CAMP?
  • CAMP holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.60/10 (Netural).